Genomma Lab Internacional SAB de CV Class B ( (GNMLF) ) has released its Q1 earnings. Here is a breakdown of the information Genomma Lab Internacional SAB de CV Class B presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Genomma Lab Internacional, S.A.B. de C.V. is a leading Mexican company in the pharmaceutical and personal care products industry, known for its broad range of premium branded products and a strong international presence. In the first quarter of 2025, Genomma Lab reported a 5.0% increase in net sales, driven by strong performance in its beverages category and productivity gains, despite challenges in the U.S. market due to a weaker flu season. The company achieved a 12.0% growth in EBITDA, with a margin expansion to 23.8%, and a notable 17.7% increase in earnings per share. Key financial highlights include a 15.4% rise in net income and a significant 62.4% increase in free cash flow. Genomma’s strategic focus on core brands resulted in growth in five out of its nine categories, with beverages and derma OTC showing strong sell-out increases. Looking ahead, Genomma Lab aims for low-teen sales growth in the mid-term by reinvesting profits in strategic projects while maintaining a robust EBITDA margin.